Alembic Pharmaceuticals Limited (BOM:533573)
India
· Delayed Price · Currency is INR | Market Cap | 157.92B |
| Revenue (ttm) | 64.19B |
| Net Income (ttm) | 6.05B |
| Shares Out | n/a |
| EPS (ttm) | 30.71 |
| PE Ratio | 26.11 |
| Forward PE | n/a |
| Dividend | 11.00 (1.35%) |
| Ex-Dividend Date | Jul 15, 2024 |
| Volume | 6,208 |
| Average Volume | 5,312 |
| Open | 826.20 |
| Previous Close | 826.20 |
| Day's Range | 802.80 - 826.95 |
| 52-Week Range | 802.80 - 1,296.15 |
| Beta | n/a |
| RSI | 22.30 |
| Earnings Date | Feb 4, 2025 |
About Alembic Pharmaceuticals
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ... [Read more]
Financial Performance
In 2023, Alembic Pharmaceuticals's revenue was 62.29 billion, an increase of 10.19% compared to the previous year's 56.53 billion. Earnings were 6.16 billion, an increase of 80.07%.
Financial StatementsNews
Stocks to watch today: M&M, BHEL, Zydus Life, Alembic Pharma, and PCBL in focus on Feb 17, 2025
Several stocks are in focus today based on key developments beyond Q3 earnings. M&M, BHEL, Zydus Life, Alembic Pharmaceuticals, and PCBL are among the notable companies making headlines. Key updates: ...
Alembic Pharmaceuticals receives USFDA approval for Brexpiprazole tablets
Alembic Pharmaceuticals Limited has achieved final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Brexpiprazole Tablets. The approved stren...
Alembic Pharmaceuticals shares surge nearly 3% on USFDA approval for Divalproex Sodium Capsules
Shares of Alembic Pharmaceuticals saw a sharp uptick of 2.38% on December 20, 2024, trading at ₹1,072.75, following the company’s announcement of receiving final approval from the USFDA for its Abbrev...
Alembic Pharmaceuticals secures USFDA approval for Divalproex Sodium Delayed-Release Capsules USP, 125 mg
Alembic Pharmaceuticals Limited, a prominent player in the global pharmaceutical industry, announced on December 20, 2024, that it has received final approval from the United States Food & Drug Admini...
Alembic Pharmaceuticals completes ANVISA GMP Audit for API-II Facility in Brazil
Alembic Pharmaceuticals has recently informed exchanges that the company has successfully completed the GMP audit conducted by the Brazilian Health Regulatory Agency (ANVISA) for its API-II facility i...
Alembic Pharmaceuticals receives tentative USFDA approval for olopatadine hydrochloride solution
Alembic Pharmaceuticals Limited has secured tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for olopatadine hydrochloride ophthalmic s...
Alembic Pharma shares surged nearly 5% today
Alembic Pharmaceuticals shares surged nearly 5% today – as of 9:35 am the shares were trading 4.33% higher at ₹1,086.95 on NSE. Alembic Pharmaceuticals faced a setback as the United States Food and Dr...
Alembic Pharmaceuticals secures USFDA approval for Ivabradine tablets
Alembic Pharmaceuticals Limited (Alembic) recently informed exchanges that the US Food and Drug Administration (USFDA) has granted Final Approval for its Abbreviated New Drug Application (ANDA) Ivabra...
Alembic Pharmaceuticals gains USFDA final approval for Diltiazem Hydrochloride extended-release capsules
Alembic Pharmaceuticals Limited has announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydro...
Alembic Pharma Q2 FY25 Results: Revenue jumps 3.3% YoY to ₹1,647.98 crore, net profit jumps 12.2% YoY
Alembic Pharmaceuticals reported its financial results for Q2 FY25, showing positive year-over-year (YoY) growth in both revenue and net profit, though quarter-over-quarter (QoQ) figures reflected mod...